Last month, Otsuka Holdings Co announced its planned acquisition of Astex Pharmaceuticals. The deal was priced at USD900 million according to earlier reports. The transaction between the two pharmaceutical firms would reportedly enable Otsuka to expand its portfolio with cancer therapies developed by Astex.

Today, Otsuka Holdings Co announced that its wholly owned subdidiary, Otsuka Pharmaceutical Co had successfully the acquisition of Astex Pharmaceuticals Inc. Details of the deal indicated that Astex would be acquired at USD8.50 per share piece without interest and less withholding tax. The acquisition was made through a tender offer last September 13. The acquisition would be followed by a merger on October 11.

Astex Pharmaceuticals is a California based drug manufacturer which aims to develop cancer treatments and other life threatening diseases. Meanwhile, Otsuka Holdings is a Japanese drugmaker established in 1964.

As a result of the merger, the shares of Astex Pharmaceuticals had ceased trading on the NASDAQ.